Back to Menu
1. Clinical presentation assessment
A detailed history is obtained regarding pain characteristics and progression of neurological symptoms, and neurological examination provides important diagnostic clues.
2. MRI
The first-line modality. Lesions typically show marked hyperintensity on T2-weighted imaging; contrast enhancement delineates tumor extent and relationships with adjacent structures.
3. CT
Bone-window CT demonstrates characteristic osseous destruction and associated soft-tissue mass, enabling assessment of bony involvement.
4. Pathological biopsy
The gold standard. Tissue obtained by needle or open biopsy shows physaliphorous cells within a myxoid stroma on microscopy.
5. Immunohistochemistry
Brachyury positivity is diagnostically specific and helps distinguish chordoma from other bone tumors.
6. Molecular testing
Brachyury gene testing supports diagnosis and may inform treatment selection and prognostic assessment.
7. Whole-body bone scintigraphy
Assesses skeletal involvement and detects potential bone metastases to support staging.
8. PET-CT
Evaluates metabolic activity and distant metastasis and is used for staging and response assessment.
9. Daily self-check for chordoma
Patients should monitor pain and neurological function monthly and seek specialist consultation promptly if abnormalities occur.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although chordoma is rare, it is locally destructive, and diagnostic delay can result in severe neurological dysfunction. Early and accurate diagnosis is pivotal for improving outcomes. High-risk individuals should pay attention to early warning signs and obtain timely specialist evaluation. MDT-based multidisciplinary collaboration is essential to develop individualized strategies that maximize functional preservation and prolong survival.
1. Clinical presentation assessment
A detailed history is obtained regarding pain characteristics and progression of neurological symptoms, and neurological examination provides important diagnostic clues.
2. MRI
The first-line modality. Lesions typically show marked hyperintensity on T2-weighted imaging; contrast enhancement delineates tumor extent and relationships with adjacent structures.
3. CT
Bone-window CT demonstrates characteristic osseous destruction and associated soft-tissue mass, enabling assessment of bony involvement.
4. Pathological biopsy
The gold standard. Tissue obtained by needle or open biopsy shows physaliphorous cells within a myxoid stroma on microscopy.
5. Immunohistochemistry
Brachyury positivity is diagnostically specific and helps distinguish chordoma from other bone tumors.
6. Molecular testing
Brachyury gene testing supports diagnosis and may inform treatment selection and prognostic assessment.
7. Whole-body bone scintigraphy
Assesses skeletal involvement and detects potential bone metastases to support staging.
8. PET-CT
Evaluates metabolic activity and distant metastasis and is used for staging and response assessment.
9. Daily self-check for chordoma
Patients should monitor pain and neurological function monthly and seek specialist consultation promptly if abnormalities occur.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that although chordoma is rare, it is locally destructive, and diagnostic delay can result in severe neurological dysfunction. Early and accurate diagnosis is pivotal for improving outcomes. High-risk individuals should pay attention to early warning signs and obtain timely specialist evaluation. MDT-based multidisciplinary collaboration is essential to develop individualized strategies that maximize functional preservation and prolong survival.